Raymond James raised the firm’s price target on Adma Biologics (ADMA) to $32 from $25 and keeps a Strong Buy rating on the shares. Adma’s Q1 missed slightly from a non-recurring event and higher spend, but all the fundamentals are trending positively and 2025-2026 guidance was raised still with a lot of room for upside, the analyst tells investors in a research note. The firm adds that tariffs are “not an issue” for Adma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- ADMA Biologics Reports Strong Q1 2025 Financial Growth
- ADMA Biologics Announces $500M Share Repurchase Program
- Adma Biologics options imply 10.9% move in share price post-earnings
- ADMA Biologics Inc (ADMA) Q1 Earnings Cheat Sheet
- Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz